A new type of vaccine, shown to be more than 90% effective has been approved by the UK Vaccine Taskforce. A recent study suggests Novavax has been proved to hold a stronger protection against Omicron than most other vaccines.
Novavax, a protein-based vaccine, contains antibodies that target a wide range of COVID variants including Delta, with data in December suggesting it could also combat against Omicron and be ready to tackle the “next phase” of the pandemic.
The vaccine uses more established technology than some others with early evidence it could provide less side effects with trials showing fewer rates of fatigue, headaches and muscle pain.
The Joint Committee on Vaccination and Immunisation will consider how it will be used in the UK for safe and effective use in adults over 18.
Rising COVID-19 cases amidst Omicron has left the UK with a soaring weekly average of 184,000. An order of 60 million doses is expected to be shipped by March from the Serum Institute in India, in hope to be used as a booster next autumn and winter.